Pilot evaluation of the antipruritic efficacy of a topical transient receptor potential melastatin subfamily 8 (<scp>TRPM</scp>8) agonist in dogs with atopic dermatitis and pedal pruritus

Tamamoto-Mochizuki, Chie; Murphy, Kate; Olivry, Thierry

doi:10.1111/vde.12486

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies report an improvement in barrier function and AD clinical signs when using topical lipids such as ceramides, sphingolipids, unsaturated fatty acids and essential oils 25–27 . Moreover, in a placebo‐controlled study of atopic patients with pedal pruritus, a TRPM8 agonist failed to show significant differences between the control and treatment groups 28 . One of the hypotheses that the authors put forward to account for this was the lipid content of the vehicle used in both groups 28 .…”

Section: Discussionmentioning

confidence: 99%

“…[25][26][27] Moreover, in a placebocontrolled study of atopic patients with pedal pruritus, a TRPM8 agonist failed to show significant differences between the control and treatment groups. 28 One of the hypotheses that the authors put forward to account for this was the lipid content of the vehicle used in both groups. 28 Therefore, the main limitation of this study is the lack of a placebo-control treatment.…”

Section: Discussionmentioning

confidence: 99%

“…28 One of the hypotheses that the authors put forward to account for this was the lipid content of the vehicle used in both groups. 28 Therefore, the main limitation of this study is the lack of a placebo-control treatment. The restrictive inclusion and exclusion criteria, together with the sample size (24 dogs), had sufficient statistical power to detect significant differences from baseline parameters.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and tolerance of a novel topical TRPV‐1 channel antagonist in dogs with allergic pododermatitis

Serra Fabregat,

de Pablo,

Hernán‐Pérez

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

BackgroundPruritus due to allergic skin disease is one of the most common reasons for dermatological consultations in the veterinary clinic. Treatment is usually multimodal and requires continuous monitoring and reassessment. New therapies are needed to broaden the therapeutic arsenal.Hypothesis/ObjectivesThe aim of this study was to evaluate the efficacy of a novel transient receptor potential vanilloid 1 (TRPV1) channel antagonist for allergic pododermatitis in dogs.AnimalsTwenty‐four client‐owned dogs with allergic pododermatitis.Materials and MethodsThe study was an open, prospective, multi‐centre clinical trial with client‐owned dogs. All dogs were treated twice daily with a spray containing hydroxymethoxyiodobenzyl glycolamide pelargonate for 28 days. Clinical assessments included pruritus Visual Analog Scale (PVAS), pedal skin lesion score, evaluation of quality of life (QoL), presence of secondary infections and a four‐point subjective efficacy assessment by the veterinarian and the dog owner.ResultsThere was more than 50% improvement in all scores by the conclusion of the study. Secondary infections were reduced (p < 0.001). Both the veterinarians and dog owners evaluated the efficacy of the product positively. The product was well‐tolerated.Conclusions and Clinical RelevanceThis study demonstrated the tolerability and efficacy of a TRPV1 antagonist on pruritic pododermatitis in 24 dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and tolerance of a novel topical TRPV‐1 channel antagonist in dogs with allergic pododermatitis

Serra Fabregat,

de Pablo,

Hernán‐Pérez

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

N-glycosylation state of TRPM8 protein revealed by terahertz spectroscopy and molecular modelling

Mernea

Ulăreanu

Călboreanu

et al. 2020

Biochimica et Biophysica Acta (BBA) - General Subjects

View full text Add to dashboard Cite

Histamine- and pruritogen-induced itch is inhibited by a TRPM8 agonist: a randomized vehicle-controlled human trial

Lee,

Wei,

Selescu

et al. 2024

British Journal of Dermatology

View full text Add to dashboard Cite

Background Allergies often present challenges in managing itch and the effects of histamine. Cooling agents that act via TRPM8 agonism have shown potential in itch management. However, animal studies on itch have limitations, as non-humans cannot communicate subjective events, and their fur-coated skin differs from human skin. Human studies offer more direct and reliable information. Objective This study aimed to investigate the effects of a specific TRPM8 agonist (Cryosim-1) gel on itch induced by various pruritogens in human skin. Methods Calcium imaging experiments determined the binding of Cryosim-1 and histamine to respective receptors. Thirty healthy volunteers underwent skin prick tests using pruritogens and a control vehicle. Itch and pain intensity were measured using the Numeric Rating Scale (NRS) for 10 minutes. Participants were randomly assigned to pretreatments with vehicle or TRPM8 agonist gel. Tests were repeated on a subsequent date, and skin moisture, transepidermal water loss, and mechanical sensitivity were measured. Results In vitro study confirmed that histamine is not a TRPM8 agonist, and Cryosim-1 does not act as an agonist or antagonist on hH1R. The TRPM8 agonist gel significantly reduced itch intensity for all pruritogens compared to the vehicle-only gel. It also reduced itch NRS and the integrated itch score. Mechanical sensitivity was also reduced. Conclusions The study demonstrates that the specific TRPM8 agonist gel effectively suppresses human skin itch induced by various pruritogens. These versatile actions suggest cooling agents may be promising treatments for multiple forms of itch stimuli.

show abstract

Pilot evaluation of the antipruritic efficacy of a topical transient receptor potential melastatin subfamily 8 (TRPM8) agonist in dogs with atopic dermatitis and pedal pruritus

Abstract: In this pilot trial with a TRPM8 agonist in atopic dogs with pedal pruritus, the twice daily application of a 2% Cryosim-1 cream did not have an antipruritic effect superior to that of its vehicle.

Cited by 5 publications

References 25 publications

Efficacy and tolerance of a novel topical TRPV‐1 channel antagonist in dogs with allergic pododermatitis

Efficacy and tolerance of a novel topical TRPV‐1 channel antagonist in dogs with allergic pododermatitis

N-glycosylation state of TRPM8 protein revealed by terahertz spectroscopy and molecular modelling

Histamine- and pruritogen-induced itch is inhibited by a TRPM8 agonist: a randomized vehicle-controlled human trial

Contact Info

Product

Resources

About